Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.47 |
| ▸ | CDK1 | P06493 | 6/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166090 | 0.83 | HPRT1 (0.44) | PDE2AXDHHPRT1KMT2A | |
| SCHEMBL22907592 | 0.83 | CDK2 (0.46) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL18521157 | 0.83 | CDK2 (0.46) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL2385929 | 0.83 | HPRT1 (0.55) | CDK2CDK1CCNE1CCNB1XDH | |
| SCHEMBL18520809 | 0.83 | CDK2 (0.46) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL18510386 | 0.81 | CDK2 (0.47) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL17282460 | 0.80 | CDK2 (0.44) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL22326763 | 0.80 | PDE2A (0.48) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL25469093 | 0.79 | KDM4E (0.43) | CDK2CDK1CCNE1CCNB1PDE2A | |
| SCHEMBL9910656 | 0.78 | XDH (0.42) | CDK1XDHHPRT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | ILLUMINA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | UNIV HONG KONG CHINESE (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | ILLUMINA, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230314322-A1 | SYSTEMS AND METHODS OF SEQUENCING POLYNUCLEOTIDES | ILLUMINA, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | ALIOS BIOPHARMA, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CDK2 4868/4885CDK1 4739/4885CCNE1 4880/4885 |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | CDK2 2420/4885CDK1 2487/4885CCNE1 2001/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CDK2 124/4885CDK1 199/4885CCNE1 1040/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CDK2 124/4885CDK1 199/4885CCNE1 1040/4885 |
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | NT5C2, DUT, NT5C3B | CDK2 505/4885CDK1 300/4885CCNE1 1434/4885 |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | CDK2 2475/4885CDK1 3363/4885CCNE1 3751/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | CDK2 202/4885CDK1 379/4885CCNE1 398/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | CDK2 4649/4885CDK1 3824/4885CCNE1 4804/4885 |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | NT5C3B, NSUN2, DUT | CDK2 614/4885CDK1 727/4885CCNE1 1967/4885 |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | CDK2 1508/4885CDK1 2448/4885CCNE1 3168/4885 |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | PNP, SLC29A1, SLC29A2 | CDK2 46/4885CDK1 69/4885CCNE1 310/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | CDK2 3025/4885CDK1 2787/4885CCNE1 3531/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | CDK2 423/4885CDK1 865/4885CCNE1 1498/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | CDK2 3777/4885CDK1 3738/4885CCNE1 3210/4885 |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | RNASEL, RNASE1, RNASEH1 | CDK2 1610/4885CDK1 2630/4885CCNE1 3732/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | CDK2 190/4885CDK1 382/4885CCNE1 392/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | CDK2 4714/4885CDK1 4739/4885CCNE1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.